Akers Biosciences, Inc.

If you purchased Akers Biosciences, Inc. securities and would like to join the action, please click "Join This Action" below.

AKERS MERGER INVESTIGATION: HALPER SADEH LLP ANNOUNCES INVESTIGATION INTO WHETHER THE MERGER OF AKERS BIOSCIENCES, INC. IS FAIR TO SHAREHOLDERS; INVESTORS ARE ENCOURAGED TO CONTACT THE FIRM – AKER

November 12, 2020.

New York, New York—Halper Sadeh LLP, a global investor rights law firm, is investigating whether the merger between Akers Biosciences, Inc. (NASDAQ: AKER) and MyMD Pharmaceuticals, Inc. is fair to Akers shareholders.

The investigation concerns whether Akers and its board of directors violated the federal securities laws and/or breached their fiduciary duties to shareholders. On behalf of Akers shareholders, Halper Sadeh LLP may seek increased consideration for shareholders, additional disclosures and information concerning the proposed transaction, or other relief and benefits.

Halper Sadeh LLP represents investors all over the world who have fallen victim to securities fraud and corporate misconduct. Our attorneys have been instrumental in implementing corporate reforms and recovering millions of dollars on behalf of defrauded investors.

Attorney Advertising. Prior results do not guarantee a similar outcome.

Certification

Scroll to Top